Cytopia Merger with Toronto-based YM BioSci...(anies will manage the development of fou...)

• Nimotuzumab is an EGFR-targeting antibody being developed for multiple tumour types principally in combination with radiation and chemoradiation. It is differentiated from other marketed EGFR-targeting agents by its benign side-effect profile, observed from having treated over 5,000 patients globally. The program is currently in 11 Phase II and Phase III studies by YM and its licencees and numerous additional studies worldwide.
• CYT997 is a vascular disrupting agent for the treatment of solid tumours, currently being studied in glioblastoma. This novel, small molecule compound can be differentiated from most other compounds in development because it can be administered orally as well as intravenously. The program is in two Phase II single arm studies.
• AeroLEF, an inhaled delivery composition of fentanyl for the treatment of moderate to severe acute pain, has completed a randomised Phase II study and is being prepared for late stage development internationally.
• CYT387, a specific JAK2/JAK1 kinase inhibitor, is being developed for the treatment of myeloproliferative disorders and cancer and expected to enter the clinic in the last quarter of 2009 for a Phase I/II study.
  

The merged companies will also manage other collaborations in the Cytopia portfolio including the partnership with the Commonwealth Government supported Cancer Therapeutics CRC to develop FAK inhibitors for cancer. Cytopia is holding over 4,000 tyrosine kinase inhibitors and other small molecule compounds for further development and is regularly reviewing similar such outlicensing opportunities.

Cytopia staff will continue to support the development of the CYT997 and CYT387 programs and the Melbourne based operations will be maintained. It is expected that the value of the Cytopia programs can be significantly enhanced through the resources and capabilities of
'/>"/>